Abstract
Rhinitis medicamentosa (RM), also known as ‘rebound congestion’ is inflammation of the nasal mucosa caused by the overuse of topical nasal decongestants. It classifies as a subset of drug-induced rhinitis. Topical decongestants are typically used in the relief of nasal congestion due to allergic rhinitis, acute or chronic rhinosinusitis, nasal polyps, or upper respiratory tract infection. The earliest nasal decongestants mainly derived from ephedrine, where there were reports of rebound congestion after prolonged use. This situation was found to develop as early as 3 days and up to 4 to 6 weeks of use.[1] However, with the emergence of modern vasoconstrictors, such as the imidazoline derivatives, the risk of developing RM is considered to be small or non-existent.
TY - CHAP
T1 - Rhinitis Medicamentosa
BT - StatPearls
A1 - Wahid,Nur Wahidah B.,
AU - Shermetaro,Carl,
Y1 - 2021/01//
PY - 2019/3/12/pubmed
PY - 2019/3/12/medline
PY - 2019/3/12/entrez
N2 - Rhinitis medicamentosa (RM), also known as ‘rebound congestion’ is inflammation of the nasal mucosa caused by the overuse of topical nasal decongestants. It classifies as a subset of drug-induced rhinitis. Topical decongestants are typically used in the relief of nasal congestion due to allergic rhinitis, acute or chronic rhinosinusitis, nasal polyps, or upper respiratory tract infection. The earliest nasal decongestants mainly derived from ephedrine, where there were reports of rebound congestion after prolonged use. This situation was found to develop as early as 3 days and up to 4 to 6 weeks of use.[1] However, with the emergence of modern vasoconstrictors, such as the imidazoline derivatives, the risk of developing RM is considered to be small or non-existent.
PB - StatPearls Publishing
CY - Treasure Island (FL)
UR - https://www.unboundmedicine.com/prime/citation/30855902/StatPearls:_Rhinitis_Medicamentosa
L2 - https://www.ncbi.nlm.nih.gov/books/NBK538318
DB - PRIME
DP - Unbound Medicine
ER -
